CIETAI and Sequential Radiotherapy in Squamous Lung Cancer

Central-type lung cancer refers to lung malignancies originating from the segmental bronchi and above. The most common tissue type is squamous cell carcinoma. Patients often present with cough, hemoptysis, hoarseness and also some critical conditions including superior vena caval obstruction syndrome. Therefore, effective treatment should be implemented as early as possible to rapidly reduce tumor burden and control the progression of the disease. Most of the central-type NSCLC are classified into T3-4, N1-2 stage and are non-resectable. The PACIFIC study changed the standard treatment model f

Trial Details

NCT ID
NCT05892237
Phase
PHASE2
Sponsor
Dong Wang
Status
RECRUITING
Cancer Type
Non-Small Cell (NSCLC) Lung Cancer
Interventions
  • bronchial artery interventional therapy
  • Chemotherapy drug
  • IMRT
  • Immunotherapy
Locations (sample)
  • Chongqing, Chongqing Municipality, China|29.56026,106.55771

Key Eligibility Criteria

  • Patients volunteered to participate in the study and signed the informed consent.
  • Age 18-80, both male and female.
  • Histologically or cytologically confirmed squamous lung cancer staging T3-4, Nany, and M0 (according to the American Joint Committee on Cancer Stag…
  • At least one measurable lesion according to RECIST 1.1.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Non-Small Cell (NSCLC) Lung Cancer Trials on Trialify →